A

Alliance Pharma PLC
LSE:APH

Watchlist Manager
Alliance Pharma PLC
LSE:APH
Watchlist
Price: 64.7 GBX Market Closed
Market Cap: 356.5m GBX

Relative Value

The Relative Value of one APH stock under the Base Case scenario is 98.6 GBX. Compared to the current market price of 64.7 GBX, Alliance Pharma PLC is Undervalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

APH Relative Value
Base Case
98.6 GBX
Undervaluation 34%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
46
vs Industry
52
Median 3Y
1.6
Median 5Y
2
Industry
2.6
Forward
1.7
vs History
vs Industry
1
Median 3Y
-9.4
Median 5Y
-6.3
Industry
21.7
Forward
12.4
vs History
52
vs Industry
34
Median 3Y
9
Median 5Y
9.3
Industry
16.7
vs History
28
vs Industry
6
Median 3Y
37.4
Median 5Y
33.8
Industry
23.1
vs History
25
vs Industry
47
Median 3Y
1.1
Median 5Y
1.5
Industry
2.2
vs History
47
vs Industry
44
Median 3Y
2.2
Median 5Y
2.3
Industry
2.9
Forward
2
vs History
49
vs Industry
49
Median 3Y
3.7
Median 5Y
3.8
Industry
5.5
vs History
69
vs Industry
37
Median 3Y
5.4
Median 5Y
10.8
Industry
13.2
Forward
8.6
vs History
50
vs Industry
36
Median 3Y
11.8
Median 5Y
12.5
Industry
16.8
Forward
9.7
vs History
61
vs Industry
29
Median 3Y
10.7
Median 5Y
12.6
Industry
15.9
vs History
61
vs Industry
26
Median 3Y
10.9
Median 5Y
12.7
Industry
19.2
vs History
6
vs Industry
51
Median 3Y
0.9
Median 5Y
1.2
Industry
1.9

Multiples Across Competitors

APH Competitors Multiples
Alliance Pharma PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Alliance Pharma PLC
LSE:APH
349.7m GBP 2 -32.6 5.2 12.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 17 54.9 36.9 39.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
501.5B USD 5.4 20 16.3 21.2
CH
Roche Holding AG
SIX:ROG
259.2B CHF 4.2 27.5 11.7 13.7
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 4.9 30.2 108.5 158.7
CH
Novartis AG
SIX:NOVN
207B CHF 4.7 18.1 11.5 14.8
US
Merck & Co Inc
NYSE:MRK
253.9B USD 4 13.3 9.5 11.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.3 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
144.5B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
UK
A
Alliance Pharma PLC
LSE:APH
Average P/E: 24
Negative Multiple: -32.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
18.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.3
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
A
Alliance Pharma PLC
LSE:APH
Average EV/EBITDA: 399.4
5.2
-13%
N/A
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.5
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.5
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
A
Alliance Pharma PLC
LSE:APH
Average EV/EBIT: 1 711.4
12.3
16%
0.8
US
Eli Lilly and Co
NYSE:LLY
39.5
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.2
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.7
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.3
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
8%
1.3